Was there a Section 16(b) short-swing profit related to these Immunome (IMNM) trades?

Yes. A footnote notes that certain sales were matchable with a 1,000-share purchase under Section 16(b). The director agreed to pay Immunome $155, representing the full profit realized on that specific short-swing transaction.

Immunome director offsets 10,500-share trades

Immunome Inc. director Jean Jacques Bienaimé reported offsetting trades in the company’s common stock on June 5, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Immunome Inc. director Jean Jacques Bienaimé reported offsetting trades in the company’s common stock on June 5, 2026. He made open-market purchases totaling 10,500 shares at prices between $19.27 and $19.48 per share and open-market sales totaling 10,500 shares at prices around $19.41–$19.44 per share, resulting in no net change in shares.

Following these transactions, he directly owned 43,415 shares of Immunome common stock. A footnote states that the sales were matchable with a 1,000‑share purchase under Section 16(b), and he agreed to pay $155 to Immunome, representing the full profit from that short-swing transaction.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider BIENAIME JEAN JACQUES

Role Director

Bought 10,500 shs ($204K)

Sold 10,500 shs ($204K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$19.44	$10K
Sale	Common Stock	10,000	$19.41	$194K
Purchase	Common Stock	6,000	$19.48	$117K
Purchase	Common Stock	3,500	$19.46	$68K
Purchase	Common Stock	1,000	$19.27	$19K

Holdings After Transaction: Common Stock — 43,415 shares (Direct)

Footnotes (2)

F1. The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction.
F2. The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026.

Key Figures

Shares purchased: 10,500 shares Purchase prices: $19.27–$19.48 per share Shares sold: 10,500 shares +3 more

6 metrics

Shares purchased 10,500 shares Open-market purchases of Immunome common stock on June 5, 2026

Purchase prices $19.27–$19.48 per share Prices for three purchase transactions on June 5, 2026

Shares sold 10,500 shares Open-market sales of Immunome common stock on June 5, 2026

Sale prices $19.41–$19.44 per share Prices for two sale transactions on June 5, 2026

Shares owned after trades 42,915 shares Director’s direct Immunome holdings following June 5, 2026 transactions

Short-swing profit repaid $155 Amount the director agreed to pay Immunome under Section 16(b)

Key Terms

open-market purchase, open-market sale, Section 16(b), short-swing transaction

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Section 16(b) regulatory

"matchable under Section 16(b) of the Securities Exchange Act of 1934"

A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.

short-swing transaction regulatory

"profit realized in connection with the short-swing transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunome (IMNM) director Jean Jacques Bienaimé report in this Form 4?

He reported both buying and selling Immunome common stock on June 5, 2026. The transactions involved 10,500 shares purchased and 10,500 shares sold, leaving his overall share count unchanged but updating his reported holdings and pricing details.

How many Immunome (IMNM) shares did the director trade and at what prices?

He purchased 10,500 Immunome common shares at prices between $19.27 and $19.48 and sold 10,500 shares at prices around $19.41 to $19.44. These offsetting trades resulted in no net change to his share count.

What are Jean Jacques Bienaimé’s Immunome (IMNM) holdings after these transactions?

After the reported trades, he directly holds 42,915 shares of Immunome common stock. This figure reflects his position following the June 5, 2026 open-market purchases and sales disclosed in the Form 4 insider trading report.

Do these Immunome (IMNM) trades change the director’s net ownership position?

No. The director bought and sold the same aggregate number of 10,500 shares on June 5, 2026. Because purchases and sales were equal, his net ownership level remained unchanged, though his total direct holdings are now reported as 42,915 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/09/2026 - 05:40 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last)

(First)

(Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL

WASHINGTON

98011

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2026		S⁽¹⁾⁽²⁾		500	D	$19.44	42,915	D
Common Stock	06/05/2026		S⁽¹⁾⁽²⁾		10,000	D	$19.41	32,915	D
Common Stock	06/05/2026		P⁽²⁾		6,000	A	$19.48	38,915	D
Common Stock	06/05/2026		P⁽²⁾		3,500	A	$19.46	42,415	D
Common Stock	06/05/2026		P⁽¹⁾⁽²⁾		1,000	A	$19.27	43,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction.

2. The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026.

	/s/ Sandra Stoneman, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR